title: [Pharmacological therapy of age-related macular degeneration based on etiopathogenesis].
abstract: It is of great therapeutic significance that disordered function of the vascular endothelium which supply the affected ocular structures plays a major role in the pathogenesis and development of age-related macular degeneration. Chronic inflammation is closely linked to diseases associated with endothelial dysfunction, and age-related macular degeneration is accompanied by a general inflammatory response. According to current concept, age-related macular degeneration is a local manifestation of systemic vascular disease. This recognition could have therapeutic implications because restoration of endothelial dysfunction can restabilize the condition of chronic vascular disease including age-related macular degeneration as well. Restoration of endothelial dysfunction by pharmaacological or non pharmacological interventions may prevent the development or improve endothelial dysfunction, which result in prevention or improvement of age related macular degeneration as well. Medicines including inhibitors of the renin-angiotensin system (converting enzyme inhibitors, angiotensin-receptor blockers and renin inhibitors), statins, acetylsalicylic acid, trimetazidin, third generation beta-blockers, peroxisome proliferator-activated receptor gamma agonists, folate, vitamin D, melatonin, advanced glycation end-product crosslink breaker alagebrium, endothelin-receptor antagonist bosentan, coenzyme Q10; "causal" antioxidant vitamins, N-acetyl-cysteine, resveratrol, L-arginine, serotonin receptor agonists, tumor necrosis factor-alpha blockers, specific inhibitor of the complement alternative pathway, curcumin and doxycyclin all have beneficial effects on endothelial dysfunction. Restoration of endothelial dysfunction can restabilize chronic vascular disease including age-related macular degeneration as well. Considering that the human vascular system is consubstantial, medicines listed above should be given to patients (1) who have no macular degeneration but have risk factors for the disease and are older than 50 years; (2) who have been diagnosed with unilateral age-related macular degeneration in order to prevent damage of the contralateral eye; (3) who have bilateral age-related macular degeneration in order to avert deterioration and in the hope of a potential improvement. However, randomised prospective clinical trials are still needed to elucidate the potential role of these drug treatments in the prevention and treatment of age-related macular degeneration.
authors.forename: Tamás
authors.initials: T
authors.lastname: Fischer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077300:Bosentan; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000008:administration & dosage; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage; D005492:Folic Acid / Q000008:administration & dosage; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D000069285:Infliximab / Q000008:administration & dosage; D014975:Lutein / Q000008:administration & dosage; D008268:Macular Degeneration / Q000188:drug therapy* / Q000378:metabolism*; D008550:Melatonin / Q000008:administration & dosage; D047495:PPAR gamma / Q000819:agonists; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects; D012084:Renin-Angiotensin System / Q000187:drug effects*; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage; D014292:Trimetazidine / Q000008:administration & dosage; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives; D014807:Vitamin D / Q000008:administration & dosage; D024341:Xanthophylls / Q000008:administration & dosage; D000092502:Renin Inhibitors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D001241:Aspirin; D000077300:Bosentan; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; D005492:Folic Acid; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069285:Infliximab; D014975:Lutein; D008550:Melatonin; D047495:PPAR gamma; D044140:Receptor, Angiotensin, Type 1; D000077185:Resveratrol; D013267:Stilbenes; D013449:Sulfonamides; D014292:Trimetazidine; D014409:Tumor Necrosis Factor-alpha; D014451:Ubiquinone; D014807:Vitamin D; D024341:Xanthophylls; D000092502:Renin Inhibitors; C005948:astaxanthine; C024989:coenzyme Q10; C006387:acetylsalicylsalicylic acid
keywords: age-related macular degeneration; endotheldiszfunkció; endothelial dysfunction; gyógyszeres terápia; időskori maculadegeneráció; kockázati tényező; nem gyógyszeres terápia; non-pharmacological intervention; oxidative stress; oxidatív stressz; pharmacological intervention; prevenció; primary and secondary prevention; risk factors; életmód megváltoztatása